Page 476 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Lubeck 227 CaPSURE Observation 2 yr 692 Newly diagnosed prostate Mean age: WW, 72.1 yr; RT, 70 C
1999 (WW) vs. RT (513 of cancer at enrollment in yr; RP, 62 yr
9886609 vs. RP vs. whom CaPSURE, with a minimum of 2 Only
hormonal received completed HRQoL PSA: NR controlled
c
Prospective therapy RP, RT or questionnaires since study for age
cohort WW) entry. Grade: NR

Stage: WW, T1N0M0, 26%;
T2N0M0, 64%; T3/4N0M0, 6%;
TanyN+M+, NR; unknown, 4%.
RT, T1N0M0, 39%; T2N0M0,
55%; T3/4N0M0, 5%;
TanyN+M+, 1%; unknown, NR.
RP, T1N0M0, 27%; T2N0M0,
68%; T3/4N0M0, 1%;
TanyN+M+, NR; unknown, 3%.

c Information was not extracted for patients who received hormonal therapy as their primary treatment.

C-156